Plain-English translation of NCT07686575 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new drug called ivonescimab combined with standard chemotherapy to treat advanced oral and oropharyngeal (throat) cancers that can be surgically removed. Patients receive two cycles of the medication and chemotherapy before surgery, with researchers tracking how well the treatment shrinks the tumor and studying how it affects cancer cells.
Doctors want to find better ways to treat advanced oral and throat cancers before surgery. This medication works differently than standard treatments, and early studies suggest it may help improve how well surgery works and help patients recover better.
You likely qualify if…
You likely don't qualify if…
You will receive two rounds of the new medication combined with chemotherapy, spaced three weeks apart. Before each round and before surgery, you'll provide saliva and oral swab samples. During surgery to remove your tumor, the surgeon will collect tissue samples. The entire treatment and study period lasts approximately 6–8 weeks, and your doctor will carefully monitor how well the medication is working and how you tolerate it.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China
Sponsor
Zhujiang Hospital
Enrollment target
~20 participants
Started
January 2026
Primary completion
August 2026
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xiaozhi LV
Zhujiang Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.